Is Catalyst Biosciences Inc (CBIO) a Stock to Watch After Gaining 60.00% This Week?

Monday, August 21, 2023 09:39 AM | InvestorsObserver Analysts

Mentioned in this article

Is Catalyst Biosciences Inc (CBIO) a Stock to Watch After Gaining 60.00% This Week?

Overall market sentiment has been high on Catalyst Biosciences Inc (CBIO) stock lately. CBIO receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Catalyst Biosciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CBIO!

See Full CBIO Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CBIO Stock Today?

Catalyst Biosciences Inc (CBIO) stock is trading at $0.56 as of 9:39 AM on Monday, Aug 21, an increase of $0.02, or 4.21% from the previous closing price of $0.54. The stock has traded between $0.56 and $0.60 so far today. Volume today is low. So far 12,367 shares have traded compared to average volume of 379,227 shares.

More About Catalyst Biosciences Inc

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants. Click Here to get the full Stock Report for Catalyst Biosciences Inc stock.